High Throughput Screening

高通量筛选

• 批准号: 8300297
• 负责人: MAX S. WICHA
• 金额: $ 12.51万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-06-01 至 2017-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8300297
• 关键词: Affect; Biochemical; Bioinformatics; Biological; Biological Assay; Biological Factors; Biology; Biotechnology; Cancer Biology; Cancer Center Support Grant; Cells; Cellular biology; Characteristics; Chemicals; Collaborations; Collection; Consultations; Databases; Detection; Development; Diagnosis; Disease; Enzymes; Flow Cytometry; Foundations; Funding; Genes; Genetic Models; Genome; Genomics; Goals; Human; Individual; Institution; Investments; Libraries; Malignant - descriptor; Malignant Neoplasms; Medicine; Michigan; Molecular; Molecular Models; Pathology; Pathway Analysis; Pathway interactions; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacologic Substance; Positioning Attribute; Process; Proteins; Reporter; Research; Research Personnel; Resources; Science; Scientist; Screening Result; Screening procedure; Secure; Services; Small Interfering RNA; Structure; Structure-Activity Relationship; System; Techniques; Technology; Testing; Therapeutic; Therapeutic Agents; Training; Translating; Universities; University of Michigan Comprehensive Cancer Center; assay development; base; cancer cell; clinically relevant; drug discovery; follow-up; high throughput screening; innovation; interest; molecular modeling; novel; novel therapeutics; prevent; programs; relational database; small molecule; tool

The UMCCC High-Throughput Screening (HTS) Core is a new core which offers center investigators the opportunity to translate hypothesis-driven research into clinically relevant discoveries. In general these efforts focus on dissecting the cellular and molecular mechanisms of cancer through the application of chemical genomics strategies. The UMCCC-HTS Core provides access to compound libraries, screening services, expert consultation, and information sharing for researchers interested in HTS of small molecules, natural product extracts and/or siRNA genomes. The biological and chemical collections at the core are also available for cell profile screening, targeted biology approaches and structure-based molecular modeling. The Core also provides screening to several regional universities and has ongoing collaborations with a number of outside non-profit research Institutions. The core staff assist researchers with assay development, provide training in general HTS techniques, supervise screening campaigns on biomedical targets, manage assay results In a secure relational database and provide advice on counter and secondary screening. Within the HTS Core, medicinal chemistry resources are available for consultation on appropriate follow-up compounds and structure-activity relationship (SAR) analysis. The UMCCC-HTS Core also has an alliance with the Center for Computational Medicine end Bioinformatics (CCMB) to use bioinformatics tools (ConceptGen) for analysis of siRNA HTS results (Sautor et al., 2010). The Core can fully support UMCCC objectives to Identify small molecule probes, potential therapeutic leads and genomic pathways Implicated In malignant diseases, Cancer biology (and relevant genetic models) has been investigated using biochemical and cell-based assays and many of these are amenable to HTS technologies such as flow cytometry, high-content analysis, spectrophotometric detection and transcriptional reporter systems (Collins and Workman, 2006). siRNA HTS, using whole genome or selected subsets of genes, provides pathway analysis and mechanism-based Interrogation of specific genes responsible for human cancer processes. The core and its database of screening results can be used for Individual target-based drug discovery or to Investigate specific chemotypes that affect related targets. Thus, the UMCCC-HTS core is well-positioned to facilitate the discovery of chemical probes for identification and interrogation of cancer targets at the molecular level.

UMCCC高通量筛选(HTS)核心是一个新的核心，它为中心研究人员提供了将假设驱动的研究转化为临床相关发现的机会。总体而言，这些努力侧重于通过应用化学基因组学策略来剖析癌症的细胞和分子机制。UMCCC-HTS Core为对小分子HTS、天然产品提取物和/或siRNA基因组感兴趣的研究人员提供化合物文库、筛选服务、专家咨询和信息共享。核心的生物和化学收集也可用于细胞图谱筛选、靶向生物学方法和基于结构的分子建模。该中心还为几所地区性大学提供筛选服务，并与一些外部非营利性研究机构持续开展合作。核心员工协助研究人员进行化验开发，提供常规HTS技术培训，监督生物医学靶点的筛查活动，在安全的关系数据库中管理化验结果，并提供关于计数器和二次筛查的建议。在HTS核心中，药物化学资源可用于咨询适当的后续化合物和结构-活性关系(SAR)分析。UMCCC-HTS Core还与计算医学终端生物信息学中心(CCMB)结盟，使用生物信息学工具(ConceptGen)分析siRNA HTS结果(Sautor等人，2010年)。该核心可以完全支持UMCCC的目标，以确定与恶性疾病有关的小分子探针、潜在的治疗线索和基因组途径，癌症生物学(和相关的遗传模型)已经使用生化和基于细胞的分析来研究，并且其中许多都服从高温超导技术，例如流式细胞仪、高含量分析、分光光度检测和转录报告系统(Collins和Workman，2006)。SiRNA HTS使用整个基因组或选定的基因亚集，提供对负责人类癌症过程的特定基因的途径分析和基于机制的询问。筛选结果的核心及其数据库可用于基于单个靶点的药物发现或调查影响相关靶点的特定化学类型。因此，UMCCC-HTS核心处于有利地位，可以在分子水平上促进发现用于识别和询问癌症目标的化学探针。